

Application Number	90/007,542 ✓ (90/007,859)
Filing Date	May 13, 2005
First Named Inventor	Shmuel Cabilly et al.
Examiner Name	Bennett Celsa
Attorney Docket Number	22338-10230

McReed



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 35

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
BC	07/233,430		Boss et al.	
	07/930,821		Boss et al.	
	08/320,381		Boss et al.	
	08/450,727		Boss et al.	
	08/452,420		Boss et al.	
	08/453,449		Boss et al.	
BL	4,348,376		Goldenberg	09-07-1982
	4,399,246		Goldenberg ^{90/007542 PREVIOUS 1749}	08-10-1983
BC	4,500,637		Neville, Jr. et al.	02-19-1985
	4,599,197		Wetzel	08-07-1986
	4,634,665		Axel et al.	01-06-1987
	4,668,629		Kaplan et al.	05-26-1987
	4,713,339		Levinson et al.	12-15-1987
	4,766,075		Goeddel et al.	08-23-1988
	4,792,447		Uhr et al.	12-20-1988
	4,965,196		Levinson et al.	10-23-1990
	5,081,235		Shively et al.	01-04-1992
	5,098,833		Lasky et al.	03-24-1992
	5,116,964		Capon et al.	05-26-1992
	5,179,017		Axel et al.	01-12-1993
	5,225,538		Capon et al.	07-06-1993
	5,336,603		Capon et al.	08-09-1994
	5,428,130		Capon et al.	06-27-1995
	5,455,165		Capon et al.	10-03-1995
	5,500,362		Robinson et al.	03-19-1996
	5,514,582		Capon et al.	05-07-1996
	5,585,089		Queen et al.	12-17-1996
	5,605,689		Ammann	02-25-1997
5,612,185		Uhr et al.	03-18-1997	
5,648,237		Carter	07-15-1997	
MC	5,686,072		Uhr et al.	11-11-1997


Examiner Signature	<i>[Signature]</i>	Date Considered	6/19/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

MERCK v. GENENTECH
IPR2016-01373
GENENTECH 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	2	of	35	Attorney Docket Number	22338-10230

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
ML	5,721,108		Robinson et al.	02-24-1998
	5,736,137		Anderson et al.	04-07-1998
	5,807,715		Morrison et al.	09-15-1998
	5,846,818		Robinson et al.	12-08-1998
	5,877,293		Adair et al.	03-02-1999
	5,997,867		Waldmann et al.	12-07-1999
	6,054,297		Carter et al.	04-25-2000
	6,054,561		Ring	
	6,120,767		Robinson et al.	09-19-2000
	6,204,023		Robinson et al.	03-20-2001
	6,331,415		Cabilly et al.	12-18-2001
	6,455,275		Axel et al.	09-24-2002
	6,548,640		Winter	04-15-2003


Examiner Signature		Date Considered	6/14/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
 DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			Complete if Known		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	3	of	35	Attorney Docket Number	22338-10230

FOREIGN PATENT DOCUMENTS														
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS									
					Translation	Translation	Partial	Summary	Eng. Lang.	Report	Search	PER	Abstract	Cited in
<i>MC</i>	060,057		EP	09-15-1982										
	102,634		EP	03-14-1984										
	173,494		EP	03-05-1986										
	177,343		EP	04-09-1986										
	0171496		EP	02-19-1986										
	365,997		EP	05-02-1990										
	0481790		EP	04-22-1992										
	81/02426		WO	09-03-1981										
	87/02671		WO	05-07-1987										
	89/01783		WO	03-09-1989										
	92/16553		WO	10-01-1992										
	93/07899		WO	04-29-1993										
	93/10817		WO	06-10-1993										
	97/30087		WO	08-21-1997										
	89/00999		WO	02-09-1989										
<i>MC</i>	93/21319		WO	10-28-1993										


NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	1	Abbas et al., Cellular and Molecular Immunology, Second Edition pps. 38-39 (1994)
	1	Abstract, Journal of Nuclear Medicine, May, 1990, No. 613 (Exhibit 1177, Int. No. 104,532)
	1	Abstract, The Society of Nuclear Medicine 37 th Annual Meeting, Washington Convention Center-Washington, D.C., Tuesday, June 19-Friday, June 22, 1990 (Exhibit 1180, Int. No. 104,532)
	1	Abstract, World Federation of Nuclear Medicine & Biology, Abstract submitted January 15, 1990 (Exhibit 1178, Int. no. 104,532)
	1	Achord et al. 1978. Human 0-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15:269-278
<i>MC</i>	1	Alberts et al. Molecular Biology of The Cell, pp. 285 and 375. Garland Publishing, Inc., (1983)

Examiner Signature		Date Considered	6/19/05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	4	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
BL	1	Alberts, B. Molekularbiologie der Zelle, Weinheim: VCH p. 1075 (1987)
	1	Alt et al. "Immunoglobulin heavy-chain expression and class switching in a murine leukaemia cell line," Nature, Vol. 296, p. 325-31, (Mar. 25, 1982)
	1	Andrews, D.W. and J.D. Capra. 1980. Clinical Immunobiology. pp 1-18, W.B. Sanders
	1	Arathoon, et al. - Large-Scale Cell Culture in Biotechnology pages 1390-1395, Science, Vol. 232, June 1986 (Exhibit 1157; Int. No. 104,532)
	1	Arthritis & Rheumatism, Abstract Suppl. Vol. 39, No. 9, Sept. 1996, p. S244
	1	Ashford et al. 1993 "Site-specific Glycosylation of Recombinant Rat and Human Soluble CD4 Variants Expressed in Chinese Hamster Ovary Cells", J Biol Chem., 268, 3260-3267
	1	Bagdasarian et al., "Activity of the hybrid trp-lac (lac) promoter of putida. Construction of broad-host-range, controlled-expression vectors" Gen 26 (2-3): 273-282 (December 1983)
	1	Baldwin, R.W. et al. 1990. Monoclonal Antibodies and Immunoconjugates. The Parthenon Publishing Group (UK), p. 209
	1	Banerji et al., "A Lymphocyte-Specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes," Cell, Vol. 33, 729-740 (July 1982)
	1	J. Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts", Cancer Res. (1988) 58: 2825-2831
	1	Beatty et al., Cancer Research (Suppl.) 50:922s-926s (February 1, 1990) (Exhibit 1011; Int. No. 104,532)
	1	Beatty et al., Cancer Research 49:1587-1594 (March 15, 1989) (Exhibit 1010; Int. No. 104,532)
	1	Begent et al., Br. J. Cancer, 62:487 (1990) (Exhibit 1088; Int. No. 104,532)
	1	Benoist, C., et al., "In vivo sequence requirements of the SV40 early promoter region," Nature, 290: 304-310 (1981)
	1	Bergman, Y., et al., "Two regulatory elements for immunoglobulin kappa light chain gene expression," Proc. Natl. Acad. Sci., 81 :7041-45 (1984)
	1	Berman et al., Science, 1983 Nov. 4; 222(4623): 524-7
	1	Bernier, "Proliferative Disorders of the Immune System," Chapter 21 (pages 622-643) in Bellanti, Immunology II (1978)
	1	Bindon et al. 1985. Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement-mediated lysis. Transplantation 40(5):538-44 (Exhibit 2072; Int. No. 104,532)
	1	Blatt, C. and J. Haimovich. 1981. The selective effect of tunicamycin on the secretion of IgM and IgG produced by the same cells. European Journal Of Immunology 11:65-66
BL	1	Blair, DG, et al., "Activation of the transforming potential of a normal cell sequence: a molecular model for oncogenesis," Science, 212: 941-43 (1981)

Examiner Signature		Date Considered	2/19/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	5	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	1	Breathnach, R., et al. "Corrected splicing of a chicken ovalbumin gene transcript in mouse L cells," <i>Proc. Natl. Acad. Sci.</i> , 77: 740-44 (1980)
	1	Bruggemann et al. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. <i>Journal of Experimental Medicine</i> 166(5):1351-61 (Exhibit 2079; Int. No. 104,532)
	1	Byrn, et al., <i>Nature</i> 344:667-670 (April 12, 1990) (Exhibit 1055; Int. No. 104,532)
	1	Cabilly, S. and A.D. Riggs. 1985. Immunoglobulin transcripts and molecular history of a hybridoma that produces antibody to carcinoembryonic antigen. <i>Gene</i> 40(1):157-61 (Exhibit 2073; Int. No. 104,532)
	1	Cabilly, Shmuel, "Growth at sub-optimal temperatures allows the production of functional, antigen-binding Fab fragments in <i>Escherichia coli</i> " <i>Gene</i> 85:553-57 (1989)
	1	<i>Cancer Principles & Practice of Oncology</i> , 5th Edition, Volume 1, Chapter 18, pages 360-372 (Exhibit 1181; Int. No. 104,532)
	1	Carter et al., "High Level <i>Escherichia coli</i> Expression and Production of a Bivalent Humanized Antibody Fragment." <i>Bio/Technology</i> 10(2):153-167 (Feb 1992)
	1	Chang, E., et al., "Transformation by cloned Harvey sarcoma virus DNA: efficiency increased by long terminal repeat DNA," <i>Science</i> , 210: 1249-51 (1980)
	1	Chang et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, pp 5640-5644 (1987) (Exhibit 1107; Int. No. 104,532)
	1	Clynes et al., 2000 "Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor antigens" <i>Nature Med</i> 6: 443-446
	1	Cobbold et al., <i>Bone Marrow Purging and Processing</i> , pages 139-154 (January 1, 1990) (Exhibit 1027; Int. No. 104,532)
	1	Cobbold, S.P. and H. Waldmann, "Therapeutic potential of monovalent monoclonal antibodies" <i>Nature</i> 308(5958):460-62 (1984) (Exhibit 2068; Int. No. 104,532)
	1	Code of Medical Ethics and Current Opinions, excerpts from pp. 339-379 (Exhibit 2269; Int. No. 104,532)
	1	Colcher et al., <i>Cancer Res.</i> 49:1738-1745 (1989) (Exhibit 1047; Int. No. 104,532)
	1	Crowe, et al., <i>A Clinical Experimental Immunology</i> , 1992, 87, pages 105-110 (Exhibit 1070; Int. No. 104,532)
	1	Davies, J., et al., "A new selective agent for eukaryotic cloning vectors," <i>Am J. Trop. Med. Hyg.</i> , 29 (5 Suppl): 1089-92 (1980)
	1	Davis et al. 1990, "High Level Expression in Chinese Hamster Ovary Cells of Soluble Forms of CD4 T Lymphocyte Glycoprotein Including Glycosylation Variants." <i>J Biol. Chem.</i> 265, 10410-10418 (Exhibit 2189; Int. No. 104,532)
	1	Davis, "Immunoglobulin molecules and genes" <i>Microbiology Including Immunology and Molecular Genetics</i> , Third edition, 1980, Chapter 17, pp. 338-379, Harper & Row, Hagerstown, MD
<i>MC</i>	1	De Waele et al. 1988. Expression in non-lymphoid cells of mouse recombinant immunoglobulin directed against the tumor marker human placental alkaline phosphatase. <i>European Journal of Biochemistry</i> 176:287-295 (Exhibit 2109; Int. No. 104,532)

Examiner Signature	<i>[Signature]</i>	Date Considered	6/15/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

Substitute for form 1449A/PTO & 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	6	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
M	1	Dean, C.J. 1994. Preparation and characterization of monoclonal antibodies to proteins and other cellular components. <i>Methods in Molecular Biology</i> 32:361-379 (Exhibit 2026; Int. No. 104,532)
	1	DeBoer, "The tac promoter: A functional hybrid derived from the trp and lac Promoters" <i>Proc. Natl. Acad. Sci. USA</i> 80:21-25 (1983)
	1	Devita et al., <i>Cancer: Principles & Practice of Oncology</i> , 1997, 5th Ed., Vol. 1, Chapter 18, VT. DeVita (Ed.), Lippincott-Raven, Philadelphia, PA
	1	Duda et al., <i>J. Surgical Oncology</i> 44:73-77 (June 1990) (Exhibit 1014; Int. No. 104,532)
	1	Dyer et al., <i>Blood</i> 73:1431-1439 (May 1, 1989) (Exhibit 1025; Int. No. 104,532)
	1	Emery & Adair, <i>Exp. Opin. Invest. Drugs</i> (1994) 3(3):241-251 (Exhibit 1087; Int. No. 104,532)
	1	Estabrook A. and J. A. K. Patterson, "Immunotherapy using monoclonal antibodies," <i>J. of Cutaneous Pathology</i> 10: 559-66 (1983).
	1	Ettinger, et al. <i>Cancer Treatment Reports</i> Vol. 83, No. 1, pages 131-134, January, 1979 (Exhibit 1129; Int. No. 104,532)
	1	Finnegan et al., <i>J. Rheumatology</i> 1997, 24:7, 1448-1449 (Exhibit 1069; Int. No. 104,532)
	1	Fittler et al., "Localization in Mouse-L-Cell Chromosomal Sites of Transferred Immunoglobulin Genes," <i>Chromosoma (Berl.)</i> 84, 717-727 (1982)
	1	Fleischman, <i>J. BioScience Reports</i> 5:893-899 (1985) (Exhibit 1080 Case No. CIV S-00-1252 WBS GGH)
	1	Frenkel et al. 1980. Analysis and detection of B cell neoplasms. <i>Blood Cells</i> 6:783-793 (Exhibit 2123; Int. No. 104,532)
	1	Friend et al., <i>Transplantation</i> 48:248-253 (August 1, 1989) (Exhibit 1023; Int. No. 104,532)
	1	Fundenberg and Kolstinen, "Human Allotype Detection by Passive Hemagglutination, with Special Reference to Immunoglobulin A Allotypes" Chapter 103 (pages 767-774) in Rose and Friedman, <i>Manual of Clinical Immunology</i> , Second Edition (1980)
	1	Geisse et al. 1996. Eukaryotic expression systems: a comparison. <i>Protein Expression and Purification</i> 8:271-282 (Exhibit 2025; Int. No. 104,532)
	1	Gillies et al., "Expression of cloned immunoglobulin genes introduced into mouse L cells," <i>Nucl. Acids Res.</i> , Vol. 11, No. 22, pp. 7982-97 (1983)
	1	Glaser et al., "Functional interrelationship between two tandem E.coli ribosomal RNA promoters" <i>Nature</i> 302(59031):74-76 (Mar 3, 1983)
	1	Goeddel et al. 1979. Direct expression in <i>Escherichia coli</i> of a DNA sequence coding for human growth hormone. <i>Nature</i> 281(5732):544-8 (Exhibit 2038; Int. No. 104,532)
M	1	Goeddel et al., "Synthesis of Human Fibroblast Interferon by E.coli" <i>Nucleic Acids Research</i> 8(18):4057-4074 (1980)

Examiner Signature		Date Considered	6/19/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	7	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	1	Goeddel, Methods in Enzymology, Volume 185, A Gene Expression Technology (1990) (Exhibit 1077; Int. No. 104,532)
	1	Gold et al. 1978. Carcinoembryonic antigen (CEA) in clinical medicine. Cancer 42:1399-1405 (Exhibit 2135; Int. No. 104,532)
	1	Goochee et al. 1991, "The Oligosaccharides of Glycoproteins: BioProcess Factors Affecting Oligosaccharide Structure and Their Effect on Glycoprotein Properties", Bio Technology 9, 1347-1355 (Exhibit 2187; Int. No. 104,532)
	1	Goochee, C. F., and T. Monica. 1990. Environmental effects on protein glycosylation. Bio Technology 8:421-427 (Exhibit 2023; Int. No. 104,532)
	1	Goodman and MacDonald, "Cloning of hormone genes from a mixture of cDNA molecules" Methods in Enzymology 68:75-90 (1979)
	1	Greipp, P. 1992. Advances in the diagnosis and management of myeloma. Seminars in Hematology 29(3: Suppl. 2):24-45 (Exhibit 2020; Int. No. 104,532)
	1	Grillo-Lopez et al. 1999. Overview of the clinical development of rituximab: first monoclonal antibody treatment approved for the treatment of lymphoma. Seminars in Oncology 26:66-73 (Exhibit 2144; Int. No. 104,532)
	1	Gross et al, "Bone marrow Purging and Processing, " International Symposium on Bone Marrow Purging and Processing (2nd, Apr. 27 and 28, 1989 Cancun, Mexico) Gross et al. (Ed.), Wiley-Liss, NY
	1	Grossbard, M.L. 1998. Monoclonal Antibody Based Therapy of Cancer. Marcel Dekker, p. 451 (Exhibit 2094; Int. No. 104,532)
	1	Gruss, P., et al., "Simian virus 40 tandem repeated sequences as an element of the early promoter," Proc. Natl. Acad. Sci., 78: 943-47 (1981)
	1	Habara et al. "Rauscher Murine Leukemia Virus: Molecular Cloning of Infectious Integrated Proviral DNA," J. of Virology, vol. 44, no. 2, pp. 731-35 (No.v 1982)
	1	Hale et al. 1985. Reactivity of rat monoclonal antibody CAMPATH- I with human leukemia cells and its possible application for autologous bone marrow transplantation. British Journal of Hematology 60(1):41-8 (Exhibit 2074; Int. No. 104,532)
	1	Hale et al. 1988. Remission induction in non Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH- I H. Lancet 2 (8625):1394-1399 (Exhibit 2015 and 1024; Int. No. 104,532)
	1	Hale et al., 1990. The Campath- I antigen (CDw52). Tissue Antigens 35:118-127 (Exhibit 2049 Int. No. 104,532)
	1	Hale, "Effects of Monoclonal Anti-lymphocyte Antibodies in Vivo in Monkeys and Humans", Mol Biol Med (1983) 1, 321-334 (Exhibit 2240; Int. No. 104,532)
	1	Hale, Progress Report (May 1990 - December 31, 1990), MRC Wellcome Therapeutic Antibody Center (Exhibit 1072; Int. No. 104,532)
	1	Hamilton, R., "Application of engineered chimeric antibodies to the calibration of human antibody standards" Annales de Biologie Clinique 49 (4):242-248 (1991)
<i>MC</i>	1	Harris, "Expression of Eukaryotic Genes in E.coli" Genetic Engineering, R.Williamson, 4 th edition pps. 127-185 (1983)

Examiner Signature	<i>MC</i>	Date Considered	6/19/06
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	8	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>ML</i>	1	Harris, et al., Proceedings of the 34th Oholo Conference, Eilat, Israel (1990) (Exhibit 1073; Int. No. 104,532)
	1	Haynes and Weissmann, "Constitutive, long-term production of human interferons by hamster cells containing multiple copies of a cloned interferon gene," (1983) Nucl. Acid. Res., Vol. 11 No. 3, pp. 687-706 (Exhibit 1109; Int. No. 104,532)
	1	Hodge, J.W. 1996. carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol and Immunother 43:127-134 (Exhibit 2032; Int. No. 104,532)
	1	Hutchins et al., Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 11980-11984 (1995)
	1	Huynh et al., 1984. Constructing and screening cDNA libraries in kgt IO and kgtl 1. DNA Cloning, Vol I- A practical Approach 49-78. Glover, D(Editor), IRL Press, Oxford (Exhibit 2050; Int. No. 104,532)
	1	Jackson and Davis, "Quantitation of Immunoglobulins," Chapter 14 (pages 109-120) in Rose and Friedman, <u>Manual of Clinical Immunology</u> , Second Edition (1980)
	1	Jefferis et al. 1998. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunological Reviews 163:59-76 (Exhibit 2095; Int. No. 104,532)
	1	Joziassse, et al., 2000 "a3-Galactosylated glycoproteins can bind to the hepaticasialoglycoprotein receptor" Eur. J Biochem. 267:6501-6508 (Exhibit 1037; Int. No. 104,532)
	1	Kabat et al. Sequences of Proteins of Immunological Interest, Bethesda, MD: National Institute of Health pps. i, xxi, xxii (1983)
	1	Khazaeli, et al., Cancer Research, 51, 5461-5466 (1991) (Exhibit 1074; Int. No. 104,532)
	1	Kabat et al., "Sequences of immunoglobulin chains: tabulation and analysis of amino acid sequences of precursors, V-regions, C-regions, J-chain and [beta]2-microglobulins" The Kabat Database of Sequences of Proteins of Immunological Interest," 1979, Publication No. 80-2008, p. 185, National Institute of Health, Bethesda, MD. (GNE-MED 52680)
	1	Kaetzel et al. 1985. Expression of biologically active bovine luteinizing hormone in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA 82:7280-7283 (Exhibit 2152; Int. No. 104,532)
	1	Kagawa Y; J Biol Chem 1988 Nov 25;263(33):17508-15 (Exhibit 1153; Int. No. 104,532)
	1	Kaufman et al. 1987. Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells. Molecular and Cellular Biology 5:1750-1759 (Exhibit 2075; Int. No. 104,532)
	1	Khazaeli et al., Manuscript - Frequent Anti-V Region Immune Response to Mouse B72.3 Monoclonal Antibody (pp 25-63)
	1	Kipriyanov et al. 1999. Generation of recombinant antibodies. Molecular Biotechnology 12:173-201 (Exhibit 2017; Int. No. 104,532)
	1	Klausner, A. "Genentech makes monoclonal precursors from E.coli" Bio/Technology 1(5):396-397(1983)
<i>ML</i>	1	Kohler, G., et al., "Immunoglobulin chain loss in hybridoma cell lines," Proc. Natl Acad. Sci., 77:2197-99 (1980)

Examiner Signature	<i>Bennett Celsa</i>	Date Considered	<i>6/19/06</i>
--------------------	----------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	9	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS


Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	1	Kohler, G. BioScience Reports 5:533-549 (1985) (Plaintiff Exhibit 1108, Case No. CIV S-00-1252 WBS GGH)
	1	Krag et al., J. Biological Chemistry, Vol. 257, No. 14, p 8424 (1983) (Exhibit 1115; Int. No. 104,532)
	1	Krag, J. Biol. Chem. 254:9167-9177 (1979) (Exhibit 1043; Int. No. 104,532)
	1	Krolick et al. 1982. In vivo therapy of a Murine B cell tumor (BCL I) using antibody-ricin a chain immunotoxins. J Exp. Med. 155:1797-1809 (Exhibit 2122; Int. No. 104,532)
	1	Kyle, "Classification and Diagnosis of Monoclonal Gammopathies," Chapter 16 (pages 135-150) in Rose and Friedman, <u>Manual of Clinical Immunology</u> , Second Edition (1980)
	1	Levy, R. and R.A. Miller. 1983. Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Ann. Rev. Med-34:107-116 (Exhibit 2121; Int. No. 104,532)
	1	Lifely et al., Glycobiology, Vol. 5 No. 8; 813-822, 1995 (Exhibit 1170; Int. No. 104,532)
	1	Lingappa et al. 1980. Signal sequences for early events in protein secretion and membrane assembly. Ann. NYAcad. Sci. 343:356-61 (Exhibit 2147; Int. No. 104,532)
	1	Linscott's Directory (formerly Catalog) of Immunological and Biological Reagents, second edition 1982-83, pp. 1-57
	1	LoBuglio and Saleh, Am. J. Medical Sciences, Sept. 1992 Vol. 304, No. 3, pp. 214-224 (Exhibit 1160; Int. No. 104,532)
	1	Liu et al., "Expression of mouse: human immunoglobulin heavy-chain cDNA in lymphoid cells" Gene 54(1):33-40 (1987)
	1	M.D. Pegram et al., "Antibody dependent cell-mediated cytotoxicity in breast cancer patients in Phase III clinical trials of a humanized anti-HER2 antibody", Proc Am. Assoc. Cancer Res., 1997, 38:602 (#4044) (Exhibit 2248; Int. No. 104,532)
	1	Ma, S. and W. Nashabeh. 1999. Carbohydrate analysis of a chimeric recombinant monoclonal antibody by capillary electrophoresis with laser-induced fluorescence detection. Analytical Chemistry 71:5185-5192 (Exhibit 2145; Int. No. 104,532)
	1	Maniatis, T., E.F. Fritsch, and J. Sambrook. 1982. Table of Contents; "Extraction, Purification, and Analysis of MRNA from Eukaryotic Cells", 187-209; "Synthesis and Cloning of CDNA", 211-246; and "Construction of Genomic Libraries", 269-307. In Molecular Cloning A Laboratory Manual, New York: Cold Spring Harbor Laboratory (Exhibit 2008; Int. No. 104,532)
	1	Margulies et al., "Regulation of immunoglobulin expression in mouse myeloma cells" Immunoglobulin Expression pp. 781-791 (1977) (GNE-MED 31462)
	1	Marx, J. Science 229:455-456 (1985) (Plaintiff Exhibit No. 1118, Case No. CIV S-00-1252 WBS GGH)
	1	Martinis et al., "Monoclonal antibodies with dual antigen specificity" Oncology pp. 311-316
	1	Matsuuchi et al. 1981. An analysis of heavy chain glycopeptides of hybridoma antibodies: correlation between antibody specificity and sialic acid content. Journal of Immunology 127(5):2188-90 (Exhibit 2060; Int. No. 104,532)
<i>MC</i>	1	Mercola et al., "Transcriptional Enhancer Elements in the Mouse Immunoglobulin Heavy Chain Locus," Science, Vol. 221, No. 4611, p. 663-65 (Aug. 12, 1983)

Examiner Signature	<i>[Signature]</i>	Date Considered	6/19/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			Complete if Known		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	10	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
M	1	Meredith et al., J. Nucl. Med, Jan. 1992, 33:23-29 (pp 13-19)
	1	Meredith et al., J. Nucl. Med., Vol 33, No. 9: 1648-1653, Sept. 1992
	1	Meredith, et al., Hum. Antibod. Hybridomas, 1993, 4:190-197 (Exhibit 1083; Int. No. 104,532)
	1	Miles Biochemicals 1979-80, p. 140-142
	1	Miller et al. "Transfection of human lymphoblastoid cells with herpes simplex viral DNA," Proc. Natl. Acad. Sci., Vol. 76, No. 2, pp. 949-53 (Feb. 1979)
	1	Morell et al. 1971. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem. 246:1461-1467 (Exhibit 2117; Int. No. 104,532)
	1	Morrison SL, et al., "A mouse myeloma variant with a defect in light chain synthesis," Eur. J. Immunol., 9:461-65 (1979)
	1	Morrison et al. 1988. Genetically engineered antibody molecules: new tools for cancer therapy. Cancer Investigation 6(2):185-92 (Exhibit 2085; Int. No. 104,532)
	1	Morrison et al. 1988. Production and characterization of genetically engineered antibody molecules. Clinical Chemistry 34(9):1668-75 (Defendant Exhibit 5009, Case No. CIV S-00-1252 WBS GGH)
	1	Morrison; S. Hospital Practice 24(10):65-80 (1989) (GNE-MED 077476)
	1	Morrison, S., "In vitro antibodies: strategies for production and application" Annual Review of Immunology 10:239-265 (1992)
	1	Mulligan, RC, et al., "Selection for animal cells that express the <i>Escherichia coli</i> gene coding for xanthine-guanine phosphoribosyltransferase," Proc. Natl. Acad. Sci., 78 :2072-76 (1980)
	1	Munro, "Uses of chimeric antibodies," Nature 312:597 (1984)
	1	Neuberger, M. TIBS 347-349 (1985) (Plaintiff Exhibit 1130 (Case No. CIV S-00-1252 WBS GGH)
	1	Neuhaus et al., JACC 14:1566-1569 (November 15, 1989) (Exhibit 1032; Int. No. 104,532)
	1	Neumaier et al., Cancer Research 50:2128-2134 (April 1, 1990) (Exhibit 1013; Int. No. 104,532)
	1	Nose, M. and H. Wigzell. 1983. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. USA 80:6632-6636 (Exhibit 2022; Int. No. 104,532)
	1	Oi et al., "Immunoglobulin Gene Expressin in Transformed Lymphoid Cells," Proc. Natl. Acad. Sci., Vol. 80, No. 3, p. 825-59 (Feb. 1, 1983)
	1	Oi & Morrison BioTechniques 4(3):214-221 (1986) (Plaintiff Exhibit 1135, Case No. CIV S-00-1252 WBS GGH)
	1	Oldham, R. 1983. Monoclonal antibodies in cancer therapy. Journal of Clinical Oncology 1:582-590 (Exhibit 2119; Int. 104,532)
	1	Orfila et al., "Immunofluorescence study of "non-idiopathic" renal amyloidosis," Hum. Pathol. 14(4):362-7 (1983)
M	1	Peakman et al., Hum. Antibod. Hybridomas 5:65-74 (1994) (Exhibit 1038; Int. No. 104,532)

Examiner Signature		Date Considered	6/19/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
 DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	11	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	1	Page et al., Biotech, 9:64-68 (1991)
	1	Picard et al., "Correct transcription of a cloned mouse immunoglobulin gene <i>in vivo</i> ," Proc. Natl. Acad. Sci., Vol. 80, pp.. 417-21 (Jan. 1983)
	1	Potamianos et al. 2000, "Radioimmunosintigraphy and Radioimmunotherapy in Cancer: Principles and Application, Anticancer Research 20, 925-948 (Exhibit 2185; Int. No. 104,532)
	1	Primus et al., Cancer Immunol. Immunotherapy (1990) 31:349-357 (Exhibit 1164; Int. No. 104,532)
	1	Queen and Baltimore, "Immunoglobulin gene transcription is activated by downstream sequence elements" Cell 33(3):741-748 (Jul 1983)
	1	Queen, C, "Comparison of mouse and human V-kappa domains" (Submitted by PDL 3/27/1997)
	1	Queen, C., "Comparison of human and mouse VH domains" (Submitted by PDL on 3/27/1997)
	1	Rademacher et al. (1988) Ann. Rev. Biochem. 57:785-838 (Exhibit 2165; Int. No. 104,532)
	1	Raju et al. 2000. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10(5):477-486 (Exhibit 2027; Int. No. 104,532)
	1	Reff et al., Blood, Vol. 83, No. 2, pp 435-445 (1994) (Exhibit 1111; Int. No. 104,532)
	1	Renner et al. 1997. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects. Leukemia 11(2):S55-S59 (Exhibit 2019; Int. No. 104,532)
	1	Rhodes and Birch Biotechnology 6:518, 521, 523 (1988) (Exhibit 1046; Int. No. 104,532)
	1	Rhodes, Adv. Anim. Cell. Biol. Technol. Bioprocess., 472-74 (1988) (Exhibit 1045; Int. No. 104,532)
	1	Riechmann et al. 1988. Expression of an antibody Fv fragment in myeloma cells. Journal of Molecular Biology 203(3):825-8 (Exhibit 2087; Int. No. 104,532)
	1	Riechmann et al. 1988. Reshaping human antibodies for therapy. Nature 322:323-327 (Exhibit 1022; Int. No. 104,532)
	1	Rosen et al. 1983. Application of monoclonal antibodies to tumor diagnosis and therapy. Annals of Clinical and Laboratory Science 13:173-184 (Exhibit 2120; Int. No. 104,532)
	1	Routledge et al., Eur. J. Immunol. 1991, 21:2717-2725 (Exhibit 1068; Int. No. 104,532)
	1	Schein et al., "Formation of Soluble Recombinant Proteins in Escherichia coli is Favored by Lower Growth Temperature" BioTechnology 6:291-294 (1988)
	1	Schein, Catherine H., "Production of soluble recombinant proteins in bacteria" Bio/Technology 7:1141-1149 (1989)
	1	Sekigawa et al., J. Virology 64:5194-5198 (October 1990) (Exhibit 1056; Int. No. 104,532)
<i>MC</i>	1	Sheeley et al., Analytical Biochemistry 247, 102-110 (1997) (Exhibit 1096; Int. No. 104,532)

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>6/19/06</i>
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	12	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	1	Sidman, C. 1981. Differing requirements for glycosylation in the secretion of related glycoproteins is determined neither by the producing cell nor by the relative number of oligosaccharide units. Journal of Biol. Chem. 256(18):9374-9376 (Exhibit 2100; Int. No. 104,532)
	1	Solomon, "Bence-Jones Proteins and Light Chains of Immunoglobulins," Scand. J. Immunol., Vol.5, 685-695 (1976)
	1	Southern, PJ et al. "Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter," J. Molec. Appl. Genet., 1:327-41 (1982)
	1	Spellman et al., 1989, J. Bio. Chem. 264:14100-14111 (Exhibit 1151; Int. No. 104,532)
	1	Stafford and Queen, "Cell-type specific expression of a transfected immunoglobulin gene" Nature 306(5938)-77-79 (Nov 3, 1983)
	1	Stevenson et al., 1989, A Chimeric Antibody With Dual Fc Regions (bisFabFc) Prepared by Manipulations at the IgG Hinge, Anti-Cancer Drug Design 3, 219-230 (Exhibit 2182; Int. No. 104,532)
	1	Stevenson et al., Blood 77:1071-1079 (March 1, 1991) (Exhibit 1026; Int. No. 104,532)
	1	Summers et al., "Stable expression in mouse cells of nuclear neoantigen after transfer of a 3.4-megadalton cloned fragment of Epstein-Barr virus DNA," Proc. Natl. Acad. Sci., Vol. 79, pp. 5688-92 (Sept. 1982)
	1	Sun et al. 1987. Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-IA. Proc. Natl Acad. Sci. 84(1):214-8 (Exhibit 2080; Int. No. 104,532)
	1	T.E. Hotaling et al., "The humanized anti-HER2 antibody rhuMAb HER2 mediates antibody dependent cell-mediated cytotoxicity via FcγR III", Proc. Am. Assoc. Cancer Res., 1996, 37:471 (#3215)
	1	Takeda et al. Nature 314:452-454 (1985) (Plaintiff Exhibit 1171, Case No. CIV S-00-1252 WBS GGH)
	1	Takei et al. 1980. Monoclonal antibody H9/25 reacts with functional subsets of T and B cells: killer, killer precursor and plaque-forming cells. European Journal of Immunology 10(7):503-9 (Exhibit 2042; Int. No. 104,532)
	1	Takeuchi et al., J. Biol. Chem., 263:3657-3663, (Exhibit 1152; Int. No. 104,532)
	1	Tan et al. 1985. A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells. Journal of immunology 135(5):3564-7 (Exhibit 2078; Int. No. 104,532)
	1	Taniguchi et al., "Expression of the Human Fibroblast Interferon Gene in Escherichia Coli", Proc. Natl. Acad. Sci. USA, 77(9):5230-5233 (Sept. 1980)
	1	Tarentino et al. 1974. The release of intact oligosaccharides from specific glycoproteins by Endo-o-N-acetylglucosaminidase H. Journal of Biological Chemistry 249:818-824 (Exhibit 2116; Int. No. 104,532)
	1	Tomimo et al., "Specificity of eluted antibody from renal tissues of patients with IgA nephropathy," Am. J. Kidney Dis. 1(5):276-80 (1982)
	1	Trill et al. 1995. Production of monoclonal antibodies in COS and CHO cells. Current Opinion in Biotechnology 6: 553-560 (Exhibit 2108; Int. No. 104,532)
	1	Tsuchiya et al. 1989. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. Journal of Hematology 16:285-90 (Exhibit 2092; Int. No. 104,532)

Examiner Signature		Date Considered	6/14/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	13	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	1	Urlaub, G. and L. A. Chasin. 1980. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. USA 77:4216-4220 (Exhibit 2031; Int. No. 104,532)
	1	Van Brunt, J. 1986. There's nothing (quite) like the real thing. Bio/Technology 4:835-839 (Exhibit 2024; Int. No. 104,532)
	1	van Nagell et al. 1980. Radioimmuno-detection of primary and metastasis ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen. Cancer Research 40(3):502-6 (Exhibit 2043; Int. No. 104,532)
	1	Verhoeyen et al. 1988. Reshaping human antibodies: grafting an antilysozyme activity. Science 239(4847):1534-6 (Exhibit 2089; Int. No. 104,532)
	1	Villiers et al. "Transcriptional 'enhancers' from SV40 and polyoma virus show a cell type preference," Nucl. Acids Res., Vol. 10, No. 24, p.7965-76 (1982)
	1	Wagener, Shively publication (Bates Nos. 0927-0934) (GNE-MED-01597)
	1	Wallick et al. 1988. Glycosylation of a VH residue of a monoclonal antibody against alpha (16) dextran increases its affinity for antigen. Journal Of Experimental Medicine 168(3):1099-109 (Exhibit 2090; Int. No. 104,532)
	1	Weidle et al. 1987. Expression of antibody CDNA in murine myeloma cells: possible involvement of additional regulatory elements in transcription of in immunoglobulin genes. Gene 60 (2-3):205-216 (Exhibit 2082; Int. No. 104,532)
	1	Weidle et al. 1987. Reconstitution of functionally active antibody directed against creatine kinase from separately expressed heavy and light chains in non-lymphoid cells. Gene 51(1):21-9 (Exhibit 2081; Int. No. 104,532)
	1	White et al., "Biologicals from recombinant microorganisms and animal cells: production and recovery," Proceedings of the 34th [i.e. 35th] OHOLO Conference, Eilat, Isreal, 1990, p. 567, White et al. (Ed.) (Exhibit 1073; Int. No. 104,532)
	1	Whittle et al., Expression in COS cells of a mouse - human chimaeric B72.3 antibody, 1987, pp. 499-505, Vol. 1, No. 6
	1	Wickens et al. 1978. Synthesis of double-stranded DNA complementary to lysozyme, ovomucoid, and ovalbumin mRNAs. Optimization for full length second strand synthesis by Escherichia coli DNA polymerase 1. Journal of Biological Chemistry 253(7):2483-95 (Exhibit 2036; Int. No. 104,532)
	1	Williams et al. Cancer Research (Suppl.) 50:1029s-1030s (February 1, 1990) (Exhibit 1012; Int. No. 104,532)
	1	Wold et al., "Introduction and expression of a rabbit beta-globin gene in mouse fibroblasts," Proc. Natl. Acad. Sci., Bol. 76, No. 11 pp. 5694-88 (Nov. 1979)
	1	Wood et al., J. Immunol., Vol. 145:3011-3016, No. 9, Nov. 1, 1990 (Exhibit 1089; Int. No. 104,532)
	1	Wright and Morrison, 1994 "Effect of Altered CH2-associated Carbohydrate Structure on the Functional Properties and In Vivo Fate of Chimeric Mouse-Human Immunoglobulin G1, J Exp. Med 180,1087-1096 (Exhibit 2186 ; Int. No. 104,532)
<i>M</i>	1	Zettlmeissl et al. 1987. Expression of biologically active human antithrombin III in Chinese hamster ovary cells. Biol Technology 5:720-5 (Exhibit 1076; Int. No. 104,532)

Examiner Signature	<i>[Signature]</i>	Date Considered	4/12/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	14	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	2	Rey Nbk #1173 (Bates Nos. 0502, 0504, 0509-0516, 0521-0522, 0525-0528, 0530-0531, 0533-0537, 0541, 0543-0544)
	2	Mumford Nbk #1246 (Bates Nos. 0615, 0617, 0626-0627, 0645)
	2	Perry Nbk #1290 (Bates Nos. 0136a-0136b, 0142-0147, 0149-0154, 0156-0158, 0160-0161, 0164-0173, 0181, 0187-0188, 0190-0192, 0197-0218, 0223, 0237, 0244-0261, 0304-0307)
	2	Wetzel Nbk #1432 (Bates Nos. 0034 0044, 0047, 0049 0050, 0053, 0061 0064, 0077 0081, 0087-0088)
	2	Holmes Spiral #4 (Bates Nos. 0825, 0830, 0837-0838, 0840-0843, 0845-0846, 0848-0849, 0852-0853, 0855, 0858)
	2	Holmes Spiral #5 (Bates Nos. 0876, 0881-0882, 0885-0887, 0889)
	2	Holmes Nbk #1446 (Bates Nos. 0941-0943, 0946-0947, 0950, 0954-0957)
	2	Perry Nbk #1683 (Bates Nos. 0336-0342, 0357-0362)
	3	File History U.S. Patent Application No. 08/909,611
	3	File History of U.S. Patent No. 5,545,404 (U.S. Patent Application No. 08/335,400) (Exhibit 2163; Int. No. 104,532)
	3	File History of U.S. Patent No. 5,545,405 (U.S. Patent Application No. 08/335,401) (Exhibit 2164; Int. No. 104,532)
	3	Robinson's U.S. Patent Application No. 07/016,202 filed January 8, 1987 (Exhibit 2153; Int. No. 104,532)
	3	Robinson's U.S. Patent Application No. 08/471,984 filed June 6, 1995 (Exhibit 2154; Int. No. 104,532)
	4	Cabilly Application No. 07/205,419 filed June 10, 1988
	4	Restriction Requirement (Paper No. 4) dated March 6, 1990 in U.S. Application No. 07/205,419
	4	Restriction Requirement (Paper No. 11) dated September 7, 1990 in U.S. Application No. 07/205,419
	4	Appointment of Associate Attorney, 3/25/91 in 07/205,419
	4	Interview Summary (Paper No. 22) in U.S. Application No. 07/205,419
	4	Amendment After Interference (Paper No. 24) filed October 4, 2001 in U.S. Application No. 07/205,419
	4	Decision Granting Petition to Correct the Assignee on the Correction Page of Application No. 07/205,419, 5/7/02
	4	File History of U.S. Patent No. 4,816,397 (Boss et al.)
	4	Declaration of Interference, 2/28/91 (Int. No. 102,572)
	4	Summary of Times Running, 2/28/91 (Int. No. 102,572)
	4	Designation of Lead Attorney (Cabilly), 3/14/91 (Int. No. 102,572)
<i>MC</i>	4	Submission of Associate Attorneys, 4/8/91 (Int. No. 102,572)

Examiner Signature	<i>[Signature]</i>	Date Considered	4/19/06
--------------------	--------------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	15	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>ML</i>	4	Revocation and Power of Attorney, 4/15/91 (Int. No. 102,572)
	4	Boss et al. Substitution of Lead Attorney, 4/19/91 (Int. No. 102,572)
	4	Associate Power of Attorney, 4/19/91 (Int. No. 102,572)
	4	Cabilly et al. Motion for Extension of Time, 5/28/91 (Int. No. 102,572)
	4	Cabilly et al. Extension of Time-Approved, 6/3/91 (Int. No. 102,572)
	4	Transmittal of Preliminary Statement of Boss et al. and Notice to Opposing Party, 6/4/91 (Int. No. 102,572)
	4	Boss et al. Motion for Benefit of its PCT Application (Boss Motion 1), 6/4/91 (Int. No. 102,572)
	4	Boss et al. Motion for Benefit of its British Application (Boss Motion 2), 6/4/91 (Int. No. 102,572)
	4	Declaration of Timothy John Roy Harris in Support of Boss Motion for Benefit of its British Application (Boss Motion 2), 6/4/91 (Int. No. 102,572)
	4	Boss et al. Motion for Judgment of Unpatentability of Cabilly Claims (Boss Motion 3), 6/4/91 (Int. No. 102,572)
	4	Certificate of Service and List of Documents Filed, 6/4/91 (Int. No. 102,572)
	4	Cabilly et al. Notice of Filing of Preliminary Statement, 6/4/91 (Int. No. 102,572)
	4	Preliminary Statement of the Party Cabilly et al., 6/4/91 (Int. No. 102,572)
	4	Cabilly et al. Request for the Exercise of Discretion Pursuant to 37 C.F.R. § 1.642, 6/4/91 (Int. No. 102,572)
	4	Boss et al. Opposition to Cabilly et al. Request Pursuant to 37 C.F.R. § 1.642, 6/24/91 (Int. No. 102,572)
	4	Opposition to Boss et al. Motion for Judgment of Unpatentability of Cabilly et al. Claims (Boss Motion 3), 6/24/91 (Int. No. 102,572)
	4	Declaration of Paul Carter In Support Of Cabilly et al Opposition to Boss et al Motion For Judgment Of Unpatentability of Cabilly et al Claims 101-120 (Boss Motion 3), 6/24/91 (Int. No. 102,572)
	4	Boss et al Reply to Opposition to Boss et al Motion for judgment of Unpatentability of Cabilly Claims, 7/9/91 (Int. No. 102,572)
	4	Decision on Motions, 7/26/91 (Int. No. 102,572)
	4	Order Regarding Testimony, 7/26/91 (Int. No. 102,572)
4	Service of Boss et al. Preliminary Statement; Boss et al. Preliminary Statement, 7/31/91 (Int. No. 102,572)	
4	Service of Cabilly et al. Preliminary Statement, 8/13/91 (Int. No. 102,572)	
4	"Communication" to PTO from Cabilly et al. (Paper #28); Information Disclosure Statement, 9/20/91 (Int. No. 102,572)	
<i>ML</i>	4	Cabilly et al. Motion for Extension of Time, 9/25/91 (Int. No. 102,572)

Examiner Signature		Date Considered	01/19/06
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	16	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>[initials]</i>	4	Decision - dismissal of "Communication" paper, 9/26/91 (Int. No. 102,572)
	4	Transmittal Letter re: Declarations of Riggs, Shively, Wetzel, Perry, Holmes, Rey, Mumford, Cabilly and Exhibits 1-20, Notice Pursuant to 37 CFR 1.671(e), 10/28/91 (Int. No. 102,572)
	4	Proposed Revision to Schedule for Records and Briefs, 12/3/91 (Int. No. 102,572)
	4	Cabilly et al. Notice of Filing Record, 1/8/92 (Int. No. 102,572)
	4	Motion by the Party Cabilly et al Pursuant to 37 CFR §1.635 to Replace Exhibits 1-20 Filed on January 8, 1992 With a Corrected Set of Exhibits and for the Return of Exhibits 1-20 Filed 1-20 On January 8, 1992, 1/22/92 (Int. No. 102,572)
	4	Corrected Submission of Stipulation Concerning Testimony, 2/5/92 (Int. No. 102,572)
	4	Cabilly et al. Motion for Extension of Time, 2/10/92 (Int. No. 102,572)
	4	Main Brief at Final Hearing of Junior Party Cabilly et al., 2/18/92 (Int. No. 102,572)
	4	Transmittal of Brief for the Party Boss et al., 3/18/92 (Int. No. 102,572)
	4	Brief at Final Hearing for Senior Party Boss et al., 2/18/92 (Int. No. 102,572)
	4	Reply Brief at Final Hearing of Junior Party Cabilly et al., 4/7/92 (Int. No. 102,572)
	4	Cabilly et al Motion Pursuant to 37 C.F. R. § 1.635 To Enter Additional Pages Into the Cabilly et al Record, 4/14/92 (Int. No. 102,572)
	4	Opposition to Cabilly et al Motion Pursuant to 37 C.F. R. §1.635 To Enter Additional Pages Into the Cabilly et al Record, 4/22/92 (Int. No. 102,572)
	4	Cabilly et al Reply to Boss et al Opposition to Cabilly et al Motion Pursuant to 37 C.F. R. § 1.635 To Enter Additional Pages Into the Cabilly et al Record, 5/7/92 (Int. No. 102,572)
	4	Notice of Filing Substitute Exhibits 8 and 20 for the Cabilly et al. Record, 5/7/92 (Int. No. 102,572)
	4	Cabilly et al. Notice of Submission of Replacement Set of Exhibits 1-20, 5/7/92 (Int. No. 102,572)
	4	Notice of Final Hearing for March 29, 1994 (paper #54), 2/4/92 (Int. No. 102,572)
	4	Cabilly et al. Supplemental Brief at Final Hearing, 4/5/92 (Int. No. 102,572)
	4	Final Decision (Priority awarded to Boss et al.) (paper #57), 8/13/98 (Int. No. 102,572)
	4	Transmittal and Filing of Agreements Under 35 USC §135(c) (Int. No. 102,572)
	4	Communication from BPAI re: Filing of agreements and request to keep separate from Interference file acknowledged (paper #59), 9/10/98 (Int. No. 102,572)
	4	Notice From PTO Requesting Communication Regarding Appeal, 11/9/98 (Int. No. 102,572)
<i>[initials]</i>	4	Belated Response to Communication Regarding Appeal, 12/1/98 (Int. No. 102,572)

Examiner Signature	<i>[Signature]</i>	Date Considered	6/19/05
--------------------	--------------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	17	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	4	Boss et al. Power to Inspect and Make Copies, 12/9/98 (Int. No. 102,572)
	4	Final Order After District Court Judgment, July 25, 2001 (Int. No. 102,572)
	4	Petition Pursuant to 37 C.F.R. § 1.666(b) for Access to Settlement Agreement (filed by Med Immune), 5/8/02 (Int. No. 102,572)
	4	Order on Petition for Access Pursuant to 35 U.S.C. § 165(c) and 37 C.F.R. § 1.666(b), 6/19/02 (Int. No. 102,572)
	4	Cabilly et al. Objection to Petition for Access to Settlement Agreement, 7/22/02 (Int. No. 102,572)
	4	Celltech's Objection to Petition for Access to Settlement Agreement, 7/22/02 (Int. No. 102,572)
	4	Reply to Objections of Celltech R&D Ltd. and Cabilly et al. to MedImmune's Petition for Access to Settlement Agreement, 8/1/02 (Int. No. 102,572)
	4	Curriculum Vitae of Art Riggs (Int. No. 102,572)
	4	Proposal to Genentech re: funding for IgG (Bates Nos. 0921-0926) (Int. No. 102,572)
	4	Curriculum Vitae of Jack Shively (Int. No. 102,572)
	4	Curriculum Vitae of Ron Wetzel (Int. No. 102,572)
	4	Curriculum Vitae of William Holmes (Int. No. 102,572)
	4	Curriculum Vitae of Michael Rey (Int. No. 102,572)
	4	Curriculum Vitae of Michael Mumford (Int. No. 102,572)
	4	Curriculum Vitae of Shmuel Cabilly (Int. No. 102,572)
4	Cabilly Nbk (Bates Nos. 0970-0976, 0982-0987, 0989, 0991-0992, 0994-01001, 01013-01014) (Int. No. 102,572)	
<i>MC</i>	5	Interference Initial Memorandum (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Observations, 4/18/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Miscellaneous Motion 10 (Suppress New Evidence Supporting Cabilly Reply 6), 4/18/2001 (Int. No. 104,532)
	5	Notice Declaring Interference, 5/15/2000 (Int. No. 104,532)
	5	Cabilly Notice of Real Party in Interest, 5/25/2000 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Notice of Reap Party in Interest, 5/26/2000 (Int. No. 104,532)
	5	Glaxo Wellcome Notice of Intent to File Preliminary Motions, 7/10/2000 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Notice of Related Litigation, 7/11/2000 (Int. No. 104,532)
<i>MC</i>	5	Glaxo Wellcome Inc. List of Preliminary Motions It Intends to File, 7/11/2000 (Int. No. 104,532)

Examiner Signature		Date Considered	6/19/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete If Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	18	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	5	Cabilly List of Preliminary Motions, 7/11/2000 (Int. No. 104,532)
	5	Cabilly Notice, 37 C.F.R. § 1.660(d), 7/11/2000 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Miscellaneous Motion 1 (with attachments), 9/28/2000 (Int. No. 104,532)
	5	Glaxo Wellcome Reply to Opposition to Miscellaneous Motion 1, 10/10/2000 (Int. No. 104,532)
	5	Order Denying Glaxo Wellcome Inc. Miscellaneous Motion 1, 10/18/2000 (Int. No. 104,532)
	5	Order Regarding Discovery, 10/26/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 1, 11/1/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 2, 11/1/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 3, 11/1/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 4, 11/1/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 5, 11/1/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 6, 11/1/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 7, 11/13/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 8, 11/13/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Motion 9, 11/13/2000 (Int. No. 104,532)
	5	Letter Regarding Error in Notice Declaring Interference, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome, Inc.'s Preliminary Motion 1, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome, Inc.'s Preliminary Motion 2, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome, Inc.'s Preliminary Motion 3, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome, Inc.'s Preliminary Motion 4, 11/1/2000 (Int. No. 104,532)
5	Glaxo Wellcome, Inc.'s Preliminary Motion 5, 11/1/2000 (Int. No. 104,532)	
5	Glaxo Wellcome, Inc.'s Preliminary Motion 6, 11/1/2000 (Int. No. 104,532)	
5	Glaxo Wellcome, Inc.'s Preliminary Motion 7, 11/1/2000 (Int. No. 104,532)	
5	Glaxo Wellcome, Inc.'s Preliminary Motion 8, 11/1/2000 (Int. No. 104,532)	
5	Glaxo Wellcome, Inc.'s Preliminary Motion 9, 11/1/2000 (Int. No. 104,532)	
<i>MC</i>	5	Glaxo Wellcome, Inc.'s Preliminary Motion 10, 11/1/2000 (Int. No. 104,532)

Examiner Signature	<i>Bennett Celsa</i>	Date Considered	6/17/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCDOCS/627594.1

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)


Sheet 19 of 35

Complete if Known

Application Number	90/007,542
Filing Date	May 13, 2005
First Named Inventor	Shmuel Cabilly et al.
Examiner Name	Bennett Celsa
Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS


Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ML	5	Glaxo Wellcome, Inc.'s Preliminary Motion 11, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome, Inc.'s Preliminary Motion 12, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome, Inc.'s Preliminary Motion 13, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome, Inc.'s Preliminary Motion 14, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Preliminary Statement, 11/8/2000 (Int. No. 104,532)
	5	Cabilly Preliminary Statement, 11/1/2000 (Int. No. 104,532)
	5	Glaxo Wellcome Objection to Admissibility of Evidence, 11/8/2000 (Int. No. 104,532)
	5	Cabilly Objection to Evidence, 11/13/2000 (Int. No. 104,532)
	5	Cabilly Miscellaneous Motion 1 (Motion for Permission to Issue a Subpoena, 35 U.S.C. § 24), 12/8/2000 (Int. No. 104,532)
	5	Opposition to Cabilly Miscellaneous Motion 1, 12/15/2000 (Int. No. 104,532)
	5	Decision Granting Cabilly Miscellaneous Motion 1, 12/20/2000 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Objection to Admissibility of Evidence 12/20/2000 (Int. No. 104,532)
	5	Cabilly Reply to Opposition to Cabilly Miscellaneous Motion 1, 12/20/2000 (Int. No. 104,532)
	5	Cabilly Response to Objections to Admissibility of Evidence, 1/16/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Miscellaneous Motion 2, 1/16/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Miscellaneous Motion 3, 1/16/2001 (Int. No. 104,532)
	5	Glaxo Response to Cabilly's Objection to Evidence, 1/16/2001 (Int. No. 104,532)
	5	Cabilly Opposition 1, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 2, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 3, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Response to Glaxo Motion 4, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 5, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 6, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 7, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 8, 2/2/2001 (Int. No. 104,532)
ML	5	Cabilly Opposition 9, 2/2/2001 (Int. No. 104,532)

Examiner Signature		Date Considered	4/19/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	90/007,542
			Filing Date	May 13, 2005
			First Named Inventor	Shmuel Cabilly et al.
			Examiner Name	Bennett Celsa
			Attorney Docket Number	22338-10230
Sheet	20	of	35	

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ML	5	Cabilly Opposition 10, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 11, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 12, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 13, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Opposition 14, 2/2/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Objection to Admissibility of Evidence, 1/23/2001 (Int. No. 104,532)
	5	Order Denying Glaxo Motions Miscellaneous Motions 1 and 2, 1/29/2001 (Int. No. 104,532)
	5	Glaxo Miscellaneous Motion 4, 2/2/2001 (Int. No. 104,532)
	5	Glaxo Miscellaneous Motion 5, 2/2/2001 (Int. No. 104,532)
	5	Glaxo Opposition to Motion 6, 2/2/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Miscellaneous Motion 6 (Correct Opp. No. 3), 3/9/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Miscellaneous Motion 7 (Correct Opp. No. 5), 3/9/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Miscellaneous Motion 8 (Correct Opp. No. 6), 3/9/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Miscellaneous Motion No. 9, 3/16/2001 (Int. No. 104,532)
	5	Glaxo Opposition to Motion 1, 2/2/2001 (Int. No. 104,532)
	5	Glaxo Opposition to Motion 2, 2/2/2001 (Int. No. 104,532)
	5	Glaxo Opposition to Motion 3, 2/2/2001 (Int. No. 104,532)
	5	Glaxo Opposition to Motion 4, 2/2/2001 (Int. No. 104,532)
	5	Glaxo Opposition to Motion 5, 2/2/2001 (Int. No. 104,532)
	ML	5
5		Glaxo Opposition to Motion 7, 2/2/2001 (Int. No. 104,532)
5		Glaxo Opposition to Motion 8, 2/2/2001 (Int. No. 104,532)
5		Glaxo Opposition to Motion 9, 2/2/2001 (Int. No. 104,532)
	5	Cabilly Response to Glaxo Miscellaneous Motion 4, 2/8/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Objection to Admissibility of Evidence, 2/9/2001 (Int. No. 104,532)
	5	Order Granting Glaxo Miscellaneous Motion 4, 2/13/2001 (Int. No. 104,532)

Examiner Signature		Date Considered	6/14/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	21	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>ML</i>	5	Order Authorizing Deposition Testimony, 3/5/2001 (Int. No. 104,532)
	5	Cabilly Reply 1, 3/27/2001 (Int. No. 104,532)
	5	Cabilly Reply 2, 3/27/2001 (Int. No. 104,532)
	5	Cabilly Reply 3, 3/27/2001 (Int. No. 104,532)
	5	Cabilly Reply 4, 3/27/2001 (Int. No. 104,532)
	5	Cabilly Reply 5, 3/27/2001 (Int. No. 104,532)
	5	Cabilly Reply 6, 3/27/2001 (Int. No. 104,532)
	5	Cabilly Reply 7, 3/27/2001 (Int. No. 104,532)
	5	Cabilly Reply 8, 3/27/2001 (Int. No. 104,532)
	5	Cabilly Reply 9, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 1, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 2, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 3, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 4, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 5, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 6, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 7, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 8, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 9, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 11, 3/27/2001 (Int. No. 104,532)
	5	Glaxo Reply 14, 3/27/2001 (Int. No. 104,532)
	5	Order Granting Glaxo Wellcome Inc. Miscellaneous Motions, 4/2/2001 (Int. No. 104,532)
	5	Cabilly Response to Objection to Admissibility of Evidence, 2/22/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc. Objection to Admissibility of Evidence, 4/3/2001 (Int. No. 104,532)
	5	Transcript of teleconference with APJ on 4/5/2001 (Int. No. 104,532)
<i>ML</i>	5	Order Authorizing Glaxo Supplemental Opposition 6, 4/6/2001 (Int. No. 104,532)

Examiner Signature	<i>[Signature]</i>	Date Considered	4/19/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	22	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ML	5	Cabilly Motion to Suppress, 37 C.F.R. § 1.656(h), 4/18/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Request for Defer Decision on Motions Until Final Hearing or to Permit the Filing of Briefs, 4/18/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Miscellaneous Motion 11(Suppression of Certain Deposition Exhibits and Deposition Testimony), 4/18/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Miscellaneous Motion 12 (Suppression of Deposition Testimony), 4/18/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Notice of Change of Real Party in Interest, 4/19/2001 (Int. No. 104,532)
	5	Petition from the April 6, 2001 Order of the APJ Under 37 C.F.R. 1.644(a)(1), 4/20/2001 (Int. No. 104,532)
	5	Memorandum Opinion and Order, 4/30/2001 (Int. No. 104,532)
	5	Order Regarding Glaxo Wellcome Inc. Motions, 5/2/2001 (Int. No. 104,532)
	5	Cabilly's Opposition to Glaxo Miscellaneous Motion 10, 5/2/01 (Int. No. 104,532)
	5	Cabilly's Opposition to Glaxo Wellcome Misc. Motion 11, 5/2/2001 (Int. No. 104,532)
	5	Cabilly's Opposition to Glaxo Wellcome Misc. Motion 12, 5/2/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Opposition to Cabilly Motion to Suppress (With exhibits attached), 5/2/2001 (Int. No. 104,532)
	5	Cabilly's Reply to Glaxo's Supplemental Opposition to Preliminary Motion 6, 6/1/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Objection to Admissibility of Evidence, 6/8/2001 (Int. No. 104,532)
	5	Glaxo Wellcome's Reply to Cabilly's Opposition to Misc. Motion 10, 7/2/2001 (Int. No. 104,532)
	5	Glaxo Wellcome's Reply to Cabilly's Oppositions to Misc. Motion 11, 7/2/2001 (Int. No. 104,532)
	5	Glaxo Wellcome's Reply to Cabilly's Oppositions to Misc. Motion 12, 7/2/2001 (Int. No. 104,532)
	5	Cabilly Reply to the Opposition to It's Motion to Suppress Evidence, 7/2/2001 (Int. No. 104,532)
	5	Submission of Transcript of Oral Hearing Held 9/18/01, 9/24/2001 (Int. No. 104,532)
	5	Order Making Visual Aid of Record, 9/27/2001 (Int. No. 104,532)
	5	Order Regarding Filing of Glaxo Supplemental Evidence, 11/13/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Submission of Late Evidence, 11/15/2001 (Int. No. 104,532)
	5	Cabilly Motion to Suppress, 11/20/2001 (Int. No. 104,532)
	5	Glaxo Wellcome Inc.'s Opposition to Cabilly Motion to Suppress, 11/21/2001 (Int. No. 104,532)
ML	5	Cabilly Reply to Glaxo Opposition to Motion To Suppress, 11/27/2001 (Int. No. 104,532)

Examiner Signature	<i>Bennett Celsa</i>	Date Considered	4/19/06
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDCS/627594.1

Substitute for form 1449A/PTO & 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	23	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>ML</i>	5	Decision on Preliminary and Other Motions and Final Judgment, Sept. 4, 2002 (Int. No. 104,532)
	6	Cabilly Exhibit List (Int. No. 104,532)
	6	Notice of Allowability, Paper No. 21 dated June 13, 1995 in U.S. Patent Application No. 08/155,864 (Exhibit 1006; Int. No. 104,532)
	6	Notice of Allowability, Paper No. 9 dated June 7, 1995 in U.S. Patent Application No. 08/335,400 (Exhibit 1007; Int. No. 104,532)
	6	Notice of Allowability, Paper No. 9 dated June 8, 1995 in U.S. Patent Application No. 08/335,401 (Exhibit 1008; Int. No. 104,532)
	6	Declaration of Stephen V. Desiderio, M.D., Ph.D. (Exhibit 1028; Int. No. 104,532)
	6	Declaration of Sharon S. Krag, Ph.D. (Exhibit 1029; Int. No. 104,532)
	6	Declaration of John E. Shively, Ph.D. (Exhibit 1030; Int. No. 104,532)
	6	Activase™7 (Alteplase) package insert dated June 1988 (Exhibit 1033; Int. No. 104,532)
	6	Declaration of James Scott Crowe, Paper No. 16, received in executed form in Group 1800 on November 17, 1994 in U.S. Patent Application No. 08/155,864 (Exhibit 1034; Int. No. 104,532)
	6	Declaration of Robert Lively, Paper No. 10; received in executed form in Group 1800 on April 12, 1994 in U.S. Patent Application No. 08/155,864 (Exhibit 1035; Int. No. 104,532)
	6	Declaration of Geoffrey Hale, Paper No. 16, received in executed form in Group 1800 on November 17, 1994 in U.S. Patent Application No. 08/155,864 (Exhibit 1036; Int. No. 104,532)
	6	Curriculum Vitae of John E. Shively, Ph.D. (Exhibit 1039; Int. No. 104,532)
	6	Curriculum Vitae of Stephen V. Desiderio, M.D., Ph.D. (Exhibit 1040; Int. 104,532)
	6	Curriculum Vitae of Sharon S. Krag, Ph.D. (Int. 104,532)
	6	Citation of Information, dated September 6, 1995 in U.S. Patent Application No. 08/335,400 (Exhibit 1049; Int. No. 104,532)
	6	Citation of Information, Paper No. 14 dated September 6, 1995 in U.S. Patent Application No. 08/335,401 (Exhibit 1050; Int. No. 104,532)
	6	Examiner Communication, Paper No. 30 dated May 16, 1996 in U.S. Patent Application No. 08/155,864 (Exhibit 1051; Int. No. 104,532)
	6	Examiner Communication dated December 29, 1995 in U.S. Patent Application No. 08/335,400 (Exhibit 1052; Int. No. 104,532)
<i>ML</i>	6	Examiner Communication, Paper No. 15 dated January 5, 1996 in U.S. Patent Application No. 08/335,401 (Exhibit 1053; Int. No. 104,532)

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>6/14/06</i>
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	24	of	35	Attorney Docket Number	22338-10230


NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>ML</i>	6	Office Action dated March 10, 1992, Paper No. 5 in U.S. Patent Application No. 07/770,730, filed October 16, 1991 (Exhibit 1057; Int. No. 104,532)
	6	Preliminary Amendment, Paper No. 9 in U.S. Application Serial No. 08/155,864, filed November 23, 1993 in U.S. Application Serial No. 08/155,864, filed November 23, 1993
	6	Preliminary Amendment of March 30, 1994 submitted in U.S. Patent Application No. 08/155,864 (Exhibit 1058; Int. No. 104,532)
	6	Declaration of Robert Lively, submitted in U.S. Patent Application No. 08/155,864, dated June 4, 1994 (Exhibit 1059; Int. No. 104,532)
	6	Preliminary Communication, Paper No. 15, received in Group 1800 on November 17, 1994 in U.S. Patent Application No. 08/155,864 (Exhibit 1060; Int. No. 104,532)
	6	Declaration of Geoffrey Hale, submitted in U.S. Patent Application No. 08/155,864, dated November 16, 1994 (Exhibit 1062; Int. No. 104,532)
	6	Amendment in U.S. Patent Application No. 08/155,864 dated 2/28/1995 (Exhibit 1063; Int. No. 104,532)
	6	Office Action dated January 6, 1995, Paper No. 4 in U.S. Patent Application No. 08/335,400, filed November 3, 1994 (Exhibit 1064; Int. No. 104,532)
	6	Amendment of May 8, 1995 submitted in U.S. Patent Application No. 08/335,400 (Exhibit 1065; Int. No. 104,532)
	6	Office Action dated January 11, 1995, Paper No. 4 in U.S. Patent Application No. 08/335,401, filed November 3, 1994 (Exhibit 1066; Int. No. 104,532)
	6	Amendment dated May 8, 1995, Paper No. 7 in U.S. Patent Application No. 08/335,400 to Page (Exhibit 1067; Int. No. 104,532)
	6	Second Declaration of Sharon S. Krag, Ph.D. (Exhibit 1071; Int. No. 104,532)
	6	Third Declaration of Sharon S. Krag, Ph.D. (Exhibit 1075; Int. No. 104,532)
	6	Amendment filed in U.S. Patent Application No. 08/909,611 (Exhibit 1081; Int. No. 104,532)
	6	Declaration of Steven B. Kelber (Exhibit 1085; Int. No. 104,532)
	6	Protocol UAC 180 of the University of Alabama's Comprehensive Cancer Center, describing Clinical Phase I trials conducted over the period November 1989 through October, 1990. (See in particular, § 5.1, page 9.) (Exhibit 1090; Int. No. 104,532)
	6	Data Report for Protocol UAC 180 dated 08-24-1990: Patient data collected after administration of cB72.3 monoclonal antibody (Exhibit 1093; Int. No. 104,532)
	6	Status Report: Phase I Contract Cancer Therapy Evaluation Program No1-CM-97611 dated 02-4-1992 (pp 1-12) (Exhibit 1094; Int. No. 104,532)
	6	James Scott Crowe Deposition Transcript (Exhibit 1100; Int. No. 104,532)
<i>M</i>	6	Methods in Enzymology, Vol. 101, Part C, Table of Contents, p v-viii (Exhibit 1101; Int. No. 104,532)

Examiner Signature	<i>[Signature]</i>	Date Considered	4/19/05
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	25	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
MC	6	Yarranton Deposition Transcript and Supporting Exhibits (Exhibit 1112; Int. No. 104,532)
	6	Second Declaration of Stephen V. Desiderio, M.D., Ph.D. (Exhibit 1113; Int. No. 104,532)
	6	LoBuglio Deposition Transcript (Exhibit 1114; Int. No. 104,532)
	6	Fourth Declaration of Sharon S. Krag, Ph.D. (Exhibit 1117; Int. No. 104,532)
	6	Deposition Transcript of Ellen Vitetta, 1/08/01 (Exhibit 1120; Int. No. 104,532)
	6	Deposition Transcript of Richard Youle 1/3/01 (Exhibit 1121; Int. No. 104,532)
	6	Third Declaration of Stephen V. Desiderio, M.D., Ph.D. (Exhibit 1122; Int. No. 104,532)
	6	Deposition Transcript of Sharon Krag 1/5/01 (Exhibit 1123; Int. No. 104,532)
	6	Deposition Transcript of Stephen Desiderio 12/28/00 (Exhibit 1125; Int. No. 104,532)
	6	ATCC deposit verification for CEA.66-E3 - (Exhibit 1126; Int. No. 104,532)
	6	Chart Entitled "A Human Leucocyte Surface Markers by Immunotech" (Exhibit 1127; Int. No. 104,532)
	6	Excerpts from Prosecution File History of 5,545,403 (U.S. Patent Application No. 08/155,864) (not entire file history) (Exhibit 1154; Int. No. 104,532)
	6	Excerpts from Prosecution File History of 5,545,404 (U.S. Patent Application No. 08/335,400) (not entire file history) (Exhibit 1155; Int. No. 104,532)
	6	Transcript from Second Deposition of Robert Lively, Ph.D. (Exhibit 1165; Int. No. 104,532)
	6	Transcript from Deposition of Nicholas Rapson, Ph.D. (Exhibit 1166; Int. No. 104,532)
	6	Transcript from Second Deposition of James Scott Crowe, Ph.D. (Exhibit 1167; Int. No. 104,532)
	6	Transcript from Second Deposition of Richard Youle, Ph.D. (Exhibit 1168; Int. No. 104,532)
	6	Deposition of Vitetta 3/18/2001 (Exhibit 1169; Int. No. 104,532)
	6	Transcript from Second Deposition of Sharon Krag, Ph.D. (Exhibit 1171; Int. No. 104,532)
	6	Deposition Transcript of Mark Sydenham (Exhibit 1172; Int. No. 104,532)
	6	Excerpts from Prosecution File History of U.S. Patent Application No. 08/155,864 (Exhibit 1173; Int. No. 104,532)
	6	Declaration of Vladimir Drozdoff, Ph.D. (Exhibit 1174; Int. No. 104,532)
	6	Verdict - United States District Court, District of Delaware (Exhibit 1175; Int. No. 104,532)
	6	Ellen Vitetta Deposition Transcript, May 21, 2001 (Exhibit 1176; Int. No. 104,532)
6	Linda Thurmond Deposition Transcript, May 18, 2001 (Exhibit 1179; Int. No. 104,532)	

Examiner Signature		Date Considered	6/19/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
 DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	26	of	35	Attorney Docket Number	22338-10230


NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	7	Glaxo Wellcome Inc. Exhibit List (Int. No. 104,532)
	7	Office Action dated May 27, 1999 from Cabilly's U.S. Patent Application No. 08/909,611 (Paper 14) (Exhibit 2001; Int. No. 104,532)
	7	Declaration of John Ridgway dated June 17, 1999 (with attached Exhibit A) from Cabilly's U.S. Patent Application No. 08/909,611 (Paper 15) (Exhibit 2002; Int. No. 104,532)
	7	Interview Summary dated June 22, 1999 from Cabilly's U.S. Patent Application No. 08/909,611 (Paper 16) (Exhibit 2003; Int. No. 104,532)
	7	Interview Summary dated July 12, 1999 from Cabilly's U.S. Patent Application No. 08/909,611 (Paper 17) (Exhibit 2004; Int. No. 104,532)
	7	Office Action dated March 2, 2000 from Cabilly's U.S. Patent Application No. 08/909,611 (Paper 18) (Exhibit 2005; Int. No. 104,532)
	7	Headings in the Cabilly Application (Exhibit 2010; Int. No. 104,532)
	7	Curriculum Vitae of Dr. Richard Youle (Exhibit 2011; Int. No. 104,532)
	7	Declaration 1 of Dr. Richard Youle (Exhibit 2012; Int. No. 104,532)
	7	CD Molecules printout ("Human cell surface molecule recognized by the International Workshops on Human Leukocyte Differentiation Antigens"), Protein Reviews on the Web (Exhibit 2018; Int. No. 104,532)
	7	Vitetta Declaration 1 (Dr. Ellen Vitetta) (Exhibit 2028; Int. No. 104,532)
	7	Lifely Declaration with Exhibits dated April 6, 1994 (Exhibit 2033; Int. No. 104,532)
	7	Medline Abstracts regarding rat anti-CDw52 therapeutic antibodies (Exhibit 2051; Int. No. 104,532)
	7	File History of Page's U.S. Patent Application No. 07/777,730, filed October 16, 1991 (Exhibit 2056; Int. No. 104,532)
	7	Curriculum Vitae of Dr. Ellen Vitetta (Exhibit 2058; Int. No. 104,532)
	7	Medline Abstracts regarding murine anti-CD4 therapeutic antibodies (Exhibit 2064; Int. No. 104,532)
	7	Crowe Declaration with Exhibits (Exhibit 2088; Int. No. 104,532)
	7	Cabilly Claims Corresponding to the Count (Exhibit 2096; Int. No. 104,532)
	7	Availability of CEA.66-E3 (Exhibit 2097; Int. No. 104,532)
	7	Declaration 2 of Dr. Richard Youle (Exhibit 2098; Int. No. 104,532)
	7	EPO Communication dated June 2, 1987 during prosecution of Cabilly et al. European Application No. 84302368.0-2105 (Exhibit 2111; Int. No. 104,532)
<i>MC</i>	7	January 29, 1987 response of Cabilly et al. filed before EPO during prosecution of Cabilly et al. European Application No. 84302368.0-2105 (Exhibit 2112; Int. No. 104,532)

Examiner Signature	<i>Bennett Celsa</i>	Date Considered	<i>4/15/06</i>
--------------------	----------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
 DCDOCS/627594.1

Substitute for form 1449A/PTO & 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	27	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ML	7	Search results of ATCC product listing of deposited cell lines (Exhibit 2114; Int. No. 104,532)
	7	Legal Analysis Concerning Written Description (Exhibit 2126; Int. No. 104,532)
	7	Amendment dated May 8, 1995, Paper No. 7 in U.S. Patent Application No. 08/335,400 (Exhibit 2133; Int. No. 104,532)
	7	Amendment of May 11, 1995 submitted in U.S. Patent Application No. 08/335,401 (Exhibit 2134; Int. No. 104,532)
	7	Genentech, Inc.'s released product sales for Rituxan (Exhibit 2139; Int. No. 104,532)
	7	Genentech Reports 25 Percent Increase in Product Sales for Third Quarter (from Genentech web site) (Exhibit 2140; Int. No. 104,532)
	7	Genentech Reports 1999 Year-End Results (from Genentech web site) (Exhibit 2141; Int. No. 104,532)
	7	Cancer data sheet from the National Cancer Institute "CancerNet" internet site (Exhibit 2142; Int. No. 104,532)
	7	FDA Product Description Sheet (Exhibit 2143; Int. No. 104,532)
	7	Datasheet on CD52 from Workshop on Leukocyte Antigens (Exhibit 2146; Int. No. 104,532)
	7	Declaration 3 of Dr. Richard Youle (Exhibit 2148; Int. No. 104,532)
	7	Declaration 4 of Dr. Richard Youle (Exhibit 2130; Int. No. 104,532)
	7	Datasheet on CD4 from Workshop on Leukocyte Antigens (Exhibit 2151; Int. No. 104,532)
	7	File History of Page's U.S. Patent Application No. 07/943,146, filed September 10, 1992 (Exhibit 2149; Int. No. 104,532)
	7	File History of Page's U.S. Patent Application No. 08/046,893, filed April 15, 1993 (Exhibit 2150; Int. No. 104,532)
	7	Request for Admissions 1-11 - Rituxan (Exhibit 2155; Int. No. 104,532)
	7	Herceptin - description sheets (4 pages) (Exhibit 2156; Int. No. 104,532)
	7	Vitetta Declaration 2 (Exhibit 2157; Int. No. 104,532)
	7	Youle Declaration 5 (Exhibit 2159; Int. No. 104,532)
	7	Mark Sydenham Declaration (Exhibit 2160; Int. No. 104,532)
7	Declaration 2 of J. Scott Crowe (Exhibit 2161; Int. No. 104,532)	
7	Robinson's U.S. Patent Application No. 09/021,934, filed February 12, 1998 and selected papers from the file wrapper (Exhibit 2162; Int. No. 104,532)	
7	Hale Declaration (Exhibit 2167; Int. No. 104,532)	
ML	7	Youle Declaration 6 (Exhibit 2169; Int. No. 104,532)


Examiner Signature		Date Considered	6/16/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

Substitute for form 1449A/PTO & 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	28	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ML	7	Deposition Transcript of Ellen Vitetta, Ph.D., 1/8/01 (Exhibit 2170; Int. No. 104,532)
	7	Deposition Transcript of James S. Crowe 12/14/00 (Exhibit 2171; Int. No. 104,532)
	7	VS Form 16-6A - U.S Veterinary Permit for Importation and Transportation of Controlled Materials and Organisms and Vectors - Permit No. 27899 - Date Issued: 11/8/91 - Re: Campath 1H MONOCLONAL ANTIBODY (Exhibit 2172; Int. No. 104,532)
	7	Internal Notice of Shipment of Campath 1H May 10, 1990 (Exhibit 2173; Int. No. 104,532)
	7	Deposition Transcript of Stephen V. Desiderio, 12/28/00 (Exhibit 2177; Int. No. 104,532)
	7	Deposition Transcript of Mark Robert Lively 1/9/00 (Exhibit 2180; Int. No. 104,532)
	7	Deposition Transcript of John Shively 1/12/01 (Exhibit 2181; Int. No. 104,532)
	7	Cabilly Claims 53-67 (Exhibit 2184; Int. No. 104,532)
	7	March 6, 1989 Memorandum from Jeffrey M. Johnston, M.D. Re: CAMPATH and Rheumatoid Arthritis Overview Medical Position (Exhibit 2191; Int. No. 104,532)
	7	March 28, 1989 - Lab Meeting - handwritten notes - FIRST MENTION OF CAMPATH- 1H, 3 pages (Exhibit 2190; Int. No. 104,532)
	7	July 13, 1989 - handwritten notes - 4 pages (Exhibit 2192; Int. 104,532)
	7	June 11, 1990 -Laboratory Notebook 90/0522, lodination of C- I H (Exhibit 2193; Int. No. 104,532)
	7	CV of Linda Thurmond (Exhibit 2194; Int. No. 104,532)
	7	CV of Mark Sydenham (Exhibit 2195; Int. No. 104,532)
	7	131 Declaration of Rapson (Exhibit 2196; Int. No. 104,532)
	7	131 Declaration of Thurmond (Exhibit 2197; Int. No. 104,532)
	7	Declaration 4 of James Scott Crowe (Exhibit 2198; Int. No. 104,532)
	7	P73 CAMPATH-IH Project Team Meeting Minutes - February 6, 1990 (Exhibit 2199; Int. No. 104,532)
	7	Laboratory Notebook (Exhibit 2201; Int. No. 104,532)
	7	Laboratory Notebook (Exhibit 2202; Int. No. 104,532)
	7	Laboratory Notebook (Exhibit 2203; Int. No. 104,532)
	7	Laboratory Notebook - May 23, 1990 - Oct. 12, 1990 (Exhibit 2200; Int. No. 104,532)
	7	Laboratory Notebook - Nov. 27, 1991 - Dec. 4, 1991 (Exhibit 2204; Int. No. 104,532)
ML	7	Laboratory Notebook (Exhibit No. 2205; Int. No. 104,532)

Examiner Signature		Date Considered	6/19/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	29	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>ML</i>	7	Laboratory Notebook (Exhibit No. 2206; Int. No. 104,532)
	7	Laboratory Notebook (Exhibit 2207; Int. No. 104,532)
	7	Laboratory Notebook (Exhibit 2208; Int. No. 104,532)
	7	Laboratory Notebook (Exhibit 2209; Int. No. 104,532)
	8	Laboratory Notebook (Exhibit 2210; Int. No. 104,532)
	8	Laboratory Notebook (Exhibit 2211; Int. No. 104,532)
	8	Laboratory Notebook (Exhibit 2212; Int. No. 104,532)
	8	Laboratory Notebook (Exhibit 2213; Int. No. 104,532)
	8	Laboratory Notebook (Exhibit 2214; Int. No. 104,532)
	8	Laboratory Notebook (Exhibit 2215; Int. No. 104,532)
	8	Laboratory Notebook (Exhibit 2216; Int. No. 104,532)
	8	Laboratory Notebook (Exhibit 2217; Int. No. 104,532)
	8	CV of James S. Crowe (Exhibit 2218; Int. No. 104,532)
	8	Vitetta Declaration 3 (Exhibit 2220; Int. No. 104,532)
	8	July 13, 1989 Memorandum from Jeffrey M. Johnston to Research Committee RE: Campath-1H: A Humanized Anti-lymphocyte monoclonal antibody (Exhibit 2221; Int. No. 104,532)
	8	Thurmond Personal Notebook Entry for 6/26/89 (Exhibit 2224; Int. No. 104,532)
	8	Thurmond Personal Notebook Entry for 10/17/94 (Exhibit 2225; Int. No. 104,532)
	8	Youle Declaration 7 (Exhibit 2234; Int. No. 104,532)
	8	Herceptin description sheets from Genentech web site (16 pages) (Exhibit 2235; Int. No. 104,532)
	8	Rituxan description sheets from Genentech web site (11 pages) (Exhibit 2236; Int. No. 104,532)
8	Reuters news article and San Francisco Chronicle News article (Exhibit 2241; Int. No. 104,532)	
8	Results of Medline search of "therapeutic antibodies" years 1966-1990 (Exhibit 2242; Int. No. 104,532)	
8	Vitetta Declaration 4 (Exhibit 2243; Int. No. 104,532)	
8	Certificate of Correct Inventorship U.S. Patent No. 5,545,405, 6/17/97 (Exhibit 2245; Int. No. 104,532)	
8	Declaration of Mary Anne Armstrong (Exhibit 2249; Int. No. 104,532)	
<i>ML</i>	8	Declaration of Jeffrey J. Berns (Exhibit 2250; Int. No. 104,532)

Examiner Signature		Date Considered	6/14/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	30	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	8	Library of Congress Online Catalog record for Cabilly Exhibit 1074 (Exhibit 2251; Int. No. 104,532)
	8	Library of Congress Online Catalog record for Cabilly Exhibit 1073 (Exhibit 2256; Int. No. 104,532)
	8	National Library of Medicine PubMed MEDLINE record for Cabilly Exhibit 1074 (Exhibit 2252; Int. No. 104,532)
	8	October 17, 1994 Teleconference on Campath Long Term Follow Up (handwritten sheet and translation page) (Exhibit 2253; Int. No. 104,532)
	8	Declaration 3 of Crowe (Exhibit 2254; Int. No. 104,532)
	8	Declaration 2 of Jeffrey J. Berns (Exhibit 2255; Int. No. 104,532)
	8	Excerpts from 21 C.F.R. (Exhibit 2270; Int. No. 104,532)
	8	Vitetta Declaration 5 (Exhibit 2271; Int. No. 104,532)
	8	Supplemental 131 Declaration of Thurmond (Exhibit 2272; Int. No. 104,532)
	8	Horne v. Potton (Exhibit 2273; Int. No. 104,532)
	8	Office Action in U.S. Patent Application No. 08/046,893 to Page dated 6/23/1993 (Exhibit 2274; Int. No. 104,532)
	8	Letter dated 4/20/2001 from Jean Harney to Jerry Murphy (Exhibit 2277; Int. No. 104,532)
	8	Excerpts from Lifely Lab notebook ZEIA/90/17 (Exhibit 2278; Int. No. 104,532)
	9	Documents from EP 120694 file, namely 8/30/1988 Celltech's request to amend the application and 6/15/1990 Minutes of the Oral Proceedings
	9	Declaration of Michael Francis Tuite with CV attached (May 26, 1995) (EP 120694)
	9	Declaration of Atsuo Ochi (CV attached. Regarding EP 120694 and EP 125023 oppositions)(May 17, 1996)
	9	Declaration of Gabrielle L. Boulianne(Exhibits A-C attached. Regarding EP 120694 and EP 125023 oppositions.) (May 15, 1996)
	9	Minutes from the EP 120694 oral proceedings (Aug 13, 1996)
	9	Interlocutory Decision in Opposition Proceedings (Article 106(3)EPC) (EP 120694) (Feb 14, 1997)
	9	Decision of PCR EP 0200362 and decision of PCR EP 0201184. Sections 5 only. Submitted by PDL on 3/27/1997 (Dec 14, 1995) (EP 120694)
	9	Reasons for the Decision of T612/92 and T694/92. Submitted by PDL on 3/27/1997 (EP 120694)
	9	Appeal No. T400/97-334, Appellant: Genentech, Inc. European Patent No. 120694 (Celltech), European Patent Application No. 84301996.9, Grounds of Appeal (4/1/1997 Notice of Appeal attached) (June 13, 1997)
<i>MC</i>	9	Papers relevant to the interpretation of Ellison et al. PNAS 79:1984-1988(1982), Fig. 2 from Ellison paper and pages 203 & 211 from New England Biolabs Catalog with Ellison paper attached. Ellison paper already cited previously (EP 120694)


Examiner Signature	<i>Bennett Celsa</i>	Date Considered	<i>6/19/06</i>
--------------------	----------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

Substitute for form 1449A/PTO & 1449B/PTO			<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	90/007,542
			Filing Date	May 13, 2005
			First Named Inventor	Shmuel Cabilly et al.
			Examiner Name	Bennett Celsa
<small>(use as many sheets as necessary)</small>			Attorney Docket Number	22338-10230
Sheet	31	of	35	

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ML	9	European Patent Office communication with copy of EP 120694 maintained patent in amended form (Oct 17, 2001)
	9	Decision to Maintain the European Patent in Amended Form (Article 102(3) EPC) (Regarding EP 120694) (Mar 14, 2002)
	9	January 29, 1987 response of Cabilly et al. filed before EPO during prosecution of Cabilly et al. European Application No. 84302368.0-2105 (EP 125023)
	9	June 2, 1987 Communication from EPO Examiner during prosecution of Cabilly et al. European Application No. 84302368.0-2105 (EP 125023)
	9	Opposition to EP 125023 B of Genentech, Patentee's Response to the Opponents' Arguments (Feb 22, 1993)
	9	Response on behalf of the Patentees to the Further Submissions filed on behalf of Opponents I and IV in connection with Opposition Proceedings to EP-B-0125023 (84302368.0) (8/9/1994 Declaration of Leon R. Lyle with Exhibits A-B and 8/11/1994 Affidavit of Allan Robert Adler with Exhibits A-E) (Oct 31, 1995) (EP 125023)
	9	Genentech's request for Opponent IV to provide the subject matter to be presented by Dr. Shulman at the oral proceedings (March 3, 1997) (EP 125023)
	9	Genentech's opposition to PDL's request to admit the entire Boss file as documentation at the oral proceedings (March 18, 1997) (EP 125023)
	9	Documents submitted by Genentech prior to oral proceedings (Mar 27, 1997) (EP 125023)
	9	Decision Revoking the European Patent (Article 102(1) EPC) (EP 125,023 with Minutes attached) (Oct 16, 1997)
	9	Appeal T1212/97-334 in Re Genentech EP-B-125023 Substantiation of the Proprietor's Appeal (February 26, 1999)
	9	Genentech's suggestions on the time frame of the oral proceedings (Nov 18, 1999) (EP 125023)
	9	Opposition to European Patent No. EP-B-0125023 (84302368.0-2106) (Genentech's submission prior to the oral proceedings with affidavit from Christopher Denison dated 4/19/2000 and exhibits attached) (Apr 20, 2000)
	9	European Patent EP-B-125023 (Genentech, Inc.) Declaration of Dr. Richard Axel dated April 18, 2000 with Exhibit A
	9	Declaration of Paul J. Carter dated April 20, 2000 with Exhibit A and ATCC letter (EP 125023)
	9	Genentech's Submissions in Response to Board of Appeals' 2/2/2000 Communication. Richard Axel's 4/18/2000 Declaration with Exhibit A, Paul J. Carter's 4/20/2000 Declaration with Exhibit A, ATCC letter, Walter Moore's 4/21/2000 Statement and claim requests (Apr 21, 2000) (EP 125023)
	9	Minutes of the public oral proceedings before the Technical Board of Appeal 3.3.4 of 22 May 2000 (Regarding EP 120694) (May 22, 2000)
	9	Statement By Walter Moore (Regarding the non-availability of the Herzenberg grant application) (Apr 21, 2000)
	9	Minutes of the public oral proceedings before the Technical Board of Appeal 3.3.4 of 14 May 2001 (EP 0125023) (May 14, 2001)
ML	9	Decision of the Technical Board of Appeal 3.3.4 of 14 May 2001 (Regarding EP-B-125,023. 9/27/2001 correction to the decision attached.) (May 14, 2001)

Examiner Signature		Date Considered	9/19/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/827594.1

Substitute for form 1449A/PTO & 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	90/007,542
			Filing Date	May 13, 2005
			First Named Inventor	Shmuel Cabilly et al.
			Examiner Name	Bennett Celsa
<small>(use as many sheets as necessary)</small>			Attorney Docket Number	22338-10230
Sheet	32	of	35	

NON-PATENT LITERATURE DOCUMENTS


Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ASL	9	FOI Advisory 76-7, Procedure for Requests for Grant Applications and Progress Reports*(5/19/1976 Memo from the NIH Freedom of Information Coordinator at the US Department of Health, Education, and Welfare, and 5/10/1976 letter accompanying the memo) (May 1997)
	9	Public Information Regulation (Paragraphs 5.71(c) and 5.72 (e)only), U.S. Department of Health, Education, and Welfare (Aug 1974)
	9	Slide entitled "18 Publications Discussing Chimeric Monoclonal Antibodies Before the 1986 Application", presented at Jury trial (2002)
	9	Cabilly, S. (Letter from Shmuel Cabilly to Arthur D. Riggs) (August 5, 1980) (ND Calif, Case No. C98-3926 MMC)
	9	Genentech, Inc.'s Notice of Mot. and Mot. Summ. Adjudication on Diligence (Jul. 28, 2000), Genentech, Inc. v. Celltech Therapeutics, Ltd., No. C98-3926 MMC, 2001 U.S. Dist. LEXIS 3489 (N.D. Cal. Mar. 16, 2001)
	9	Genentech, Inc.'s Decl. of Kate H. Murashige, Ph.D., Genentech, Inc. v. Celltech Therapeutics, Ltd., No. C98-3926 MMC, 2001 U.S. Dist. LEXIS 3489 (N.D. Cal. Mar. 16, 2001)
	10	Response of Cabilly et al. filed before EPO during prosecution of Cabilly et al. European Application No. 84302368.0-2105 (February 9, 1988)
	10	Plaintiff MedImmune, Inc.'s First Amended Complaint, Demand for Jury Trial (U.S. District Court, Case No. 03-2567 MRP (CTX) MedImmune, Inc. vs. Genentech, Inc., City of Hope, and Celltech R&D Ltd.) (Aug 13, 2003)
	10	Joint Claim Construction Statement (November 7, 2003)
	10	Declaration of Dean G. Dunlavy in Support of Defendant Genentech, Inc.'s Opening Brief Regarding Claim Construction with Exhibits A-P (December 22, 2003)
	10	Joint Statement Responsive to Court's January 28, 2004 Order re: Terms to be Construed at Markman Hearing (February 9, 2004)
	10	Defendant Genentech, Inc.'s Reply Brief Regarding Claim Construction (February 13, 2004)
	10	Supplemental Declaration of Dean G. Dunlavy in Support of Defendant Genentech, Inc.'s Reply Brief Regarding Claim Construction with Exhibit Q (February 13, 2004)
	10	MedImmune, Inc.'s Responses and Objections to Genentech, Inc.'s Second Set of Interrogatories (February 24, 2004)
	10	Deposition Transcript Exhibits 1-29 of Janet Hasak (February 25, 2004)
	10	Deposition Transcript of Exhibits 30-33 of Genentech through witness, Janet Hasak (February 25, 2004)
	10	Deposition Transcript of Genentech through witness, Janet Hasak (February 25, 2004)
	10	Deposition Transcript of Wendy M. Lee and Exhibits 34-47 (March 4, 2004)
	10	Deposition Transcript of Wendy M. Lee and Exhibits 48-60 (March 5, 2004)
	10	Curriculum Vitae of Jeanne Pery
ML	11	Reporter's Transcript, Motion to Dismiss, Monday (May 21, 2001)

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>6/19/05</i>
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCDOCS/627594.1

Substitute for form 1449A/PTO & 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	33	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ML	11	Memorandum and Order (May 23, 2001)
	11	Expert Report of Deborah L. French, Ph.D., with Exhibits A, B, C (December 6, 2001)
	11	Declaration of Lewis L Lanier, Ph.D. with Exhibits A-B (January 8, 2002)
	11	Rebuttal Expert Report of Deborah L French, Ph.D. (January 25, 2002)
	11	Lanier deposition transcript (February 14, 2002)
	11	Harris deposition transcript (February 27, 2002)
	11	Transcript of Proceedings Before the Honorable Gregory G. Hollows United States Magistrate Judge Markman Hearing (March 6, 2002) (Vols. I-III)
	11	Transcript of Proceedings Before the Honorable Gregory G. Hollows United States Magistrate Judge Markman Hearing (March 7, 2002) (Vol. II)
	11	Genentech's Post-Hearing Markman Submission (March 12, 2002)
	11	Magistrate's Findings and Recommendations [Markman Hearing] (March 20, 2002)
	11	Genentech's Objections to Magistrate's Findings & Recommendations [Markman Hearing] (April 1, 2002)
	11	Genentech's Response to Chiron's Objection and Magistrate's Findings & Recommendations [Markman Hearing] April 8, 2002), with attached Exhibits
	11	Memorandum and Order [Markman] (April 22, 2002)
	11	Genentech's Second Supplemental Response to Chiron's Interrogatory No. 25 (May 13, 2002)
	11	Declaration of Lewis L. Lanier, Ph.D. in Support of Chiron's Oppositions to Genentech's Motions for Summary Judgment (May 20, 2002)
	11	Declaration of William J. Harris, PH.D. in Support of Chiron's Replies to Summary Judgment Oppositions, with Exhibits A-D (May 27, 2002)
	11	Genentech's Reply in Support of its Motion for Summary Judgment re Invalidity for Anticipation and Lack of Priority (May 28, 2002)
	11	Reporter's Transcript, Motion to Preclude Admission of Undisclosed License Agreements and Cross Motions for Summary Judgment (Monday, June 3, 2002)
	11	Memorandum and Order re: Priority, Anticipation, Written Description, Enablement, Best Mode, Utility (June 24, 2002)
	11	Supplemental Expert Report of Deborah L. French Ph.D. (July 3, 2002)
	11	Chiron's Motion for Clarification regarding Memorandum and Order re: Priority, Anticipation, Written Description, Enablement, Best Mode, Utility, or, in the alternative, Motion for Reconsideration (July 3, 2002)
ML	11	Genentech Inc.'s Proposed Jury Instructions (Phase I) (July 26, 2002)

Examiner Signature		Date Considered	6/19/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>			
			Application Number	90/007,542		
			Filing Date	May 13, 2005		
			First Named Inventor	Shmuel Cabilly et al.		
			Examiner Name	Bennett Celsa		
Sheet	34	of	35	Attorney Docket Number	22338-10230	

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ML	11	Genentech Inc.'s Responsive Trial Brief (July 26, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 6, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 8, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 9, 2002)
	12	Genentech' Inc.'s Memorandum of Points and Authorities in Support of Objections to Chiron's Proposed Limiting Instruction (August 9, 2002)
	12	Genentech Inc.'s Request for a Remedial Jury Instruction, with Exhibits A-C (August 12, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 12, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 13, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 14, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 16, 2002)
	12	Genentech's Objections to Chiron's Proposed Jury Instructions (Phase I) (August 16, 2002)
	12	Genentech's Opposition to Chiron's Motion for Judgment as a Matter of Law Under Fed. R. Civ. P.50(A), with attached testimony cited to therein (August 16, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 20, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 21, 2002)
	12	Reporter's Daily Transcript Jury Trial (August 22, 2002)
	12	Reporter's Daily Transcript, Jury Trial (September 3, 2002)
	12	Memorandum of Points and Authorities Supporting Genentech's Motion for Judgment as a Matter of Law Under Fed. R. Civ. P.50(A) (September 3, 2002)
	12	Reporter's Daily Transcript, Jury Trial (September 4, 2002)
	12	Memorandum and Order Re: Rule 50 Motions (September 11, 2002)
	12	Genentech's Opposition to Chiron's Rule 50/59 Motion, with Attached Appendix of transcript and trial transcript pages cited to therein (October 7, 2002)
	12	Memorandum and Order Re: Renewed Motion for JMOL; Motion for New Trial (October 22, 2002)
	12	Brief of Defendant-Cross-Appellant, Genentech, Inc. (May 12, 2003)
	12	<i>Chiron Corp. v. Genentech, Inc.</i> , 363 F.3d 1247 (Fed. Cir. 2004)
ML	13	Expert Report of Dr. Rodney Kellems filed August 27, 2004 in <u>In re Columbia University Patent Litigation</u> , MDL No. 1592

Examiner Signature		Date Considered	6/19/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCDOCS627594.1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			<i>Complete if Known</i>		
			Application Number	90/007,542 (90/007,559) <i>MERGED</i>	
			Filing Date	May 13, 2005	
			First Named Inventor	Shmuel Cabilly et al.	
			Examiner Name	Bennett Celsa	
Sheet	35	of	35	Attorney Docket Number	22338-10230

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Box No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>MC</i>	13	Rebuttal Expert Report of Dr. Rodney Kellems filed September 17, 2004 in <u>In re Columbia University Patent Litigation</u> , MDL No. 1592
	13	Deposition of Robert E. Kellems, October 2, 2004, taken in <u>In re Columbia University Patent Litigation</u> , MDL No. 1592
	13	Plaintiffs' Joint Contentions On Invalidity to Non-Statutory Double Patenting, served July 23, 2004 in <u>In re Columbia University Patent Litigation</u> , MDL No. 1592
	13	Exhibit 1 to Plaintiffs' Joint Contentions On Invalidity to Non-Statutory Double Patenting, served July 23, 2004 in <u>In re Columbia University Patent Litigation</u> , MDL No. 1592
	13	Exhibit 2 to Plaintiffs' Joint Contentions On Invalidity to Non-Statutory Double Patenting, served July 23, 2004 in <u>In re Columbia University Patent Litigation</u> , MDL No. 1592
	13	Decision on Motions (paper # 258), Nov. 30, 2004 (Int. No. 105, 048)
	13	Decision on Priority (paper #39), Sept. 30, 2005 (Int. No. 105, 266)
<i>MC</i>	13	Decision on Priority (paper #32), Sept. 30, 2005 (Int. No. 105, 267)

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>6/19/05</i>
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DCDOCS/627594.1